Article | March 23, 2020

Why Forecasting Trial Costs Is So Hard (And Getting Harder)

Source: Premier Research

By Daryl Fallon

Laptop Work_450by300

Forecasting the cost of clinical drug and medical device trials has never been easy, and as trials become more complex, estimating (and re-estimating) these costs becomes even more challenging.

Lack of accurate forecasts has serious schedule and cost implications. By impeding effective cash management, inaccurate projections can lead to disruptions and delays that cost sponsors and CROs some serious cash and jeopardize the development of life-changing new products.

A good budget is critical at the outset of every trial, but on Day 1 that budget becomes a forecast as you begin accounting for enrollment of new sites, protocol amendments, and change orders. At that point, even the best-conceived budget becomes a historical artifact, and what really matters is creating a real-time rolling forecast.

Learn how by using purpose-built budgeting and forecasting tools you can see what’s happening in the moment as study parameters change and adjust quickly.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader